Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2010-10-19 Investor Presentation
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Presentation to Investors 8 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a PowerPoint presentation delivered by the CEO of Biotron Limited at an investor summit. It contains detailed information about the company's business focus, clinical trial progress, drug development pipeline, market opportunity, and capital structure. The content is clearly aimed at investors and provides a strategic overview and financial highlights, typical of an investor presentation. There is no indication that this is a formal regulatory filing, annual or interim report, earnings release, or other specific report type. The document length (6940 characters) and the nature of the content support classification as an Investor Presentation rather than a brief announcement or a full financial report.
2010-10-19 English
Letter to Shareholders 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a shareholder update from Biotron Limited dated 14 October 2010. It provides detailed information about the commencement of a Phase IIa clinical trial for their drug candidate BIT225 targeting Hepatitis C and HIV. The content is a newsletter-style communication to shareholders, discussing trial design, progress, and future plans. It does not contain financial statements, earnings data, or regulatory certifications. It is not an official financial report, audit, or earnings release. It is also not a proxy, voting result, or management change announcement. The document is a communication update to shareholders about clinical trial progress and company developments, fitting the category of a shareholder update or investor communication. Given the filing categories, the closest match is "Regulatory Filings (RNS)" as a general regulatory announcement and shareholder update that does not fit other specific categories. The document length (8148 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the best classification is RNS with high confidence.
2010-10-13 English
Phase II HCV Trial Commenced 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 1 October 2010 from Biotron Limited to the ASX Limited. It informs about the commencement of a Phase IIa clinical trial for their drug BIT225 targeting Hepatitis C virus. The content focuses on the trial design, patient population, and the potential significance of the drug. There are no financial statements, regulatory certifications, or detailed financial data. The document is only 4014 characters long and reads as a news release or update rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is an operational update about a clinical trial commencement, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2010-09-30 English
Preliminary Final Report 48 pages ?Kb
Annual Report Classification · 100% confidence The document is a detailed report from Biotron Limited dated 31 August 2010, containing the Year End Accounts and Appendix 4E Preliminary Final Report for the year ended 30 June 2010. It includes an Operating and Financial Review, Directors' Report, full financial statements, notes, auditor's report, and other comprehensive information typical of a full annual report. The document references the audited Annual Report as part of the Appendix 4E filing and contains substantive financial data and analysis, including clinical trial progress, capital raising details, and patent portfolio information. The length (15,000 characters) and content confirm this is the full Annual Report rather than a brief announcement or certification. Therefore, the appropriate classification is Annual Report (10-K). FY 2010
2010-08-30 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated cash flow statements for the quarter ended 30 June 2010. It includes operating, investing, and financing cash flows, reconciliation of cash, payments to directors, and compliance statements. The document is over 7,000 characters, indicating it is a substantive report rather than a brief announcement. The content and format align with a quarterly financial report providing actual financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2010
2010-07-29 English
Presentation at International AIDS Conference 1 pag
Investor Presentation Classification · 70% confidence The document is a one-page letter dated 23 July 2010 from the company secretary of Biotron Limited addressed to the ASX Limited. It announces that data on Biotron's HIV program was presented at the XVIII International AIDS Conference. The content focuses on the presentation of scientific data and upcoming clinical trial protocols. There are no financial statements, regulatory certifications, voting results, or management changes. The document is short (2214 characters) and serves as an announcement of a presentation event rather than a detailed investor presentation or financial report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Investor Presentation (IP) because it relates to a presentation of company data to an audience, even though the document itself is a brief announcement about the presentation rather than the full presentation materials. Given the short length and nature, confidence is moderate.
2010-07-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.